Lyra Therapeutics Inc (NASDAQ: LYRA) on Monday, plunged -3.27% from the previous trading day, before settling in for the closing price of $0.27. Within the past 52 weeks, LYRA’s price has moved between $0.24 and $6.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 58.51% over the last five years. The company achieved an average annual earnings per share of -5.71%. With a float of $56.40 million, this company’s outstanding shares have now reached $57.21 million.
The firm has a total of 88 workers. Let’s measure their productivity.
Lyra Therapeutics Inc (LYRA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lyra Therapeutics Inc is 13.84%, while institutional ownership is 45.86%. The most recent insider transaction that took place on Nov 10 ’23, was worth 74,095. In this transaction Executive Chair of this company bought 25,000 shares at a rate of $2.96, taking the stock ownership to the 261,966 shares.
Lyra Therapeutics Inc (LYRA) Earnings and Forecasts
#####
According to the Wall Street analysts, stocks earnings will be around -5.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.60% during the next five years compared to -21.63% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Lyra Therapeutics Inc (LYRA) is currently performing well based on its current performance indicators. A quick ratio of 3.60 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.63, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Analysing the last 5-days average volume posted by the [Lyra Therapeutics Inc, LYRA], we can find that recorded value of 0.79 million was lower than the volume posted last year of 1.68 million. As of the previous 9 days, the stock’s Stochastic %D was 34.08%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 8.73%, which indicates a significant decrease from 23.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.79% in the past 14 days, which was higher than the 65.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2953, while its 200-day Moving Average is $2.7161. Now, the first resistance to watch is $0.2660. This is followed by the second major resistance level at $0.2750. The third major resistance level sits at $0.2810. If the price goes on to break the first support level at $0.2510, it is likely to go to the next support level at $0.2450. Should the price break the second support level, the third support level stands at $0.2360.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
Market capitalization of the company is 16.82 million based on 60,965K outstanding shares. Right now, sales total 1,560 K and income totals -62,680 K. The company made 600 K in profit during its latest quarter, and -48,130 K in sales during its previous quarter.
